| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.55(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,939 |
| 52
Week Range: |
$11.44 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
661,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$8,435,402 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
11 |
12 |
| Total Shares Sold |
0 |
10,994 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$153,810 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bickerstaff George |
Director |
– • – |
2021-05-24 |
4 |
B |
$13.46 |
$134,619 |
D/D |
10,000 |
124,560 |
2.39 |
32% |
|
| Bickerstaff George |
Director |
– • – |
2021-05-21 |
4 |
B |
$12.97 |
$129,670 |
D/D |
10,000 |
114,560 |
2.39 |
27% |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2021-05-20 |
4 |
D |
$13.32 |
$10,110 |
D/D |
(759) |
39,295 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2021-05-20 |
4 |
S |
$12.25 |
$392,064,435 |
I/I |
(32,005,260) |
0 |
|
-29% |
|
| Schlesinger Sarah J. |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,482 |
75,564 |
|
- |
|
| Haimovitz Jules |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,482 |
87,764 |
|
- |
|
| Kostas Odysseas D |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,482 |
79,560 |
|
- |
|
| Dipaolo Mark |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,482 |
75,564 |
|
- |
|
| Bickerstaff George |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,482 |
104,560 |
|
- |
|
| Birx Deborah |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,482 |
29,842 |
|
- |
|
| Birx Deborah |
Director |
– • – |
2021-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,612 |
12,360 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2021-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
10,305 |
38,399 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2021-02-19 |
4 |
D |
$11.74 |
$24,748 |
D/D |
(2,108) |
28,094 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2020-11-20 |
4 |
D |
$10.95 |
$8,738 |
D/D |
(798) |
30,202 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2020-08-20 |
4 |
D |
$13.19 |
$10,512 |
D/D |
(797) |
30,243 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2020-05-20 |
4 |
D |
$14.10 |
$12,211 |
D/D |
(866) |
31,040 |
|
- |
|
| Hulme Geoffrey |
Interim Principal Exec Officer |
• – – |
2020-05-20 |
4 |
D |
$14.10 |
$4,780 |
D/D |
(339) |
46,251 |
|
- |
|
| Schlesinger Sarah J. |
Director |
– • – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,917 |
58,082 |
|
- |
|
| Dipaolo Mark |
Director |
– • – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,917 |
58,082 |
|
- |
|
| Haimovitz Jules |
Director |
– • – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,917 |
70,282 |
|
- |
|
| Bickerstaff George |
Director |
– • – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,917 |
87,078 |
|
- |
|
| Kostas Odysseas D |
Director |
– • – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,917 |
62,078 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2020-02-24 |
4 |
S |
$14.78 |
$43,660 |
D/D |
(2,954) |
21,913 |
|
3% |
|
| Hulme Geoffrey |
Interim Principal Exec Officer |
• – – |
2020-02-20 |
4 |
D |
$15.10 |
$23,390 |
D/D |
(1,549) |
29,735 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2020-02-20 |
4 |
D |
$15.10 |
$31,302 |
D/D |
(2,073) |
24,867 |
|
- |
|
283 Records found
|
|
Page 3 of 12 |
|
|
0.27 (1.8%) 
